Chemours CC Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $563M-16.0% | $670M+9.3% | $613M+22.1% | $502M+8.2% | $464M-34.9% | ||
| $759M+11.8% | $679M-28.3% | $947M-1.3% | $959M+11.8% | $858M+11.4% | ||
| $1.54B-2.1% | $1.57B+1.4% | $1.55B-0.7% | $1.56B+0.5% | $1.55B+5.9% | ||
| $2.93B-2.4% | $3B-6.4% | $3.21B+3.5% | $3.1B+5.7% | $2.93B-2.8% | ||
| $3.04B-1.2% | $3.08B-0.6% | $3.1B-1.0% | $3.13B-0.3% | $3.14B-1.6% | ||
| $46M0.0% | $46M0.0% | $46M0.0% | $46M0.0% | $46M0.0% | ||
| $2M0.0% | $2M0.0% | $2M0.0% | $2M0.0% | $2M-33.3% | ||
| $7.27B-1.6% | $7.38B-2.2% | $7.55B+1.1% | $7.46B+1.2% | $7.38B-1.8% | ||
| $891M-6.6% | $954M-7.8% | $1.04B+1.2% | $1.02B+1.7% | $1.01B-13.0% | ||
| $37M-11.9% | $42M-19.2% | $52M+36.8% | $38M-11.6% | $43M-20.4% | ||
| $1.61B-4.6% | $1.69B-9.9% | $1.87B+2.4% | $1.83B+9.5% | $1.67B-8.4% | ||
| $4.1B0.0% | $4.1B-0.1% | $4.1B-0.1% | $4.11B+1.0% | $4.07B+0.2% | ||
| $7.05B-1.1% | $7.13B-1.9% | $7.27B+0.5% | $7.23B+6.2% | $6.81B-1.8% | ||
| $2M0.0% | $2M0.0% | $2M0.0% | $2M0.0% | $2M0.0% | ||
| $1.18B-3.4% | $1.22B-4.8% | $1.28B+2.6% | $1.25B-23.9% | $1.64B-2.6% | ||
| $215M-14.0% | $250M-8.8% | $274M+20.2% | $228M-59.7% | $566M-0.9% | ||
| $7.27B-1.6% | $7.38B-2.2% | $7.55B+1.1% | $7.46B+1.2% | $7.38B-1.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Chemours cover its short-term obligations?
- Its current ratio is 1.82 — current assets exceed current liabilities.
- Where does Chemours's balance sheet data come from?
- Every line is extracted from Chemours's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.